Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P54760: Variant p.Asn745Asp

Ephrin type-B receptor 4
Gene: EPHB4
Feedback?
Variant information Variant position: help 745 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Asparagine (N) to Aspartate (D) at position 745 (N745D, p.Asn745Asp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (N) to medium size and acidic (D) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CMAVM2. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 745 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 987 The length of the canonical sequence.
Location on the sequence: help ASGMRYLAEMSYVHRDLAAR N ILVNSNLVCKVSDFGLSRFL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         ASGMRYLAEMSYVHRDLAARNILVNSNLVCKVSDFGLSRFL

Mouse                         ASGMRYLAEMSYVHRDLAARNILVNSNLVCKVSDFGLSRFL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 16 – 987 Ephrin type-B receptor 4
Topological domain 561 – 987 Cytoplasmic
Domain 615 – 899 Protein kinase
Active site 740 – 740 Proton acceptor
Alternative sequence 307 – 987 Missing. In isoform 3.
Alternative sequence 415 – 987 Missing. In isoform 4.
Alternative sequence 517 – 987 Missing. In isoform 2.
Helix 743 – 745



Literature citations
Germline loss-of-function mutations in EPHB4 cause a second form of capillary malformation-arteriovenous malformation (CM-AVM2) deregulating RAS-MAPK signaling.
Amyere M.; Revencu N.; Helaers R.; Pairet E.; Baselga E.; Cordisco M.; Chung W.; Dubois J.; Lacour J.P.; Martorell L.; Mazereeuw-Hautier J.; Pyeritz R.E.; Amor D.J.; Bisdorff A.; Blei F.; Bombei H.; Dompmartin A.; Brooks D.; Dupont J.; Gonzalez-Ensenat M.A.; Frieden I.; Gerard M.; Kvarnung M.; Hanson-Kahn A.K.; Hudgins L.; Leaute-Labreze C.; McCuaig C.; Metry D.; Parent P.; Paul C.; Petit F.; Phan A.; Quere I.; Salhi A.; Turner A.; Vabres P.; Vicente A.; Wargon O.; Watanabe S.; Weibel L.; Wilson A.; Willing M.; Mulliken J.B.; Boon L.M.; Vikkula M.;
Circulation 136:1037-1048(2017)
Cited for: VARIANTS CMAVM2 LYS-59; PRO-74; TYR-115 DEL; 130-TRP--TYR-987 DEL; 161-VAL-LYS-162 DELINS LEU; PRO-187; 244-GLN--TYR-987 DEL; ARG-268; 352-ARG--TYR-987 DEL; 375-GLY--TYR-987 DEL; 431-ARG--TYR-987 DEL; GLY-469; ARG-516; 520-GLN--TYR-987 DEL; 596-TYR--TYR-987 DEL; TRP-656; LYS-664; THR-725; 739-ARG--TYR-987 DEL; ASP-745; ARG-789; SER-789; 806-TYR--TYR-987 DEL; ARG-807; LEU-820; THR-820; TRP-838; ARG-845; TYR-856; TRP-864 AND PRO-874; CHARACTERIZATION OF VARIANTS CMAVM2 LYS-664; TRP-838; ARG-845 AND TRP-864; INVOLVEMENT IN CMAVM2; SUBCELLULAR LOCATION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.